UnitedHealth Group

DOJ criminal probe now extends to Optum Rx physician reimbursement practices; civil Medicare-inflation probe continues — neither adjudicated in court.

DOJ criminal (Optum Rx) and civil MA-inflation probes remain pre-adjudication — not yet decided in court; July 29 Q2 earnings call is 24 days out.

DOJ criminal and civil probes (Optum Rx, MA-inflation) remain pre-adjudication — not yet decided in court; Senate finding already priced; July 29 Q2 earnings c…

DOJ criminal and civil probes (Optum Rx, MA-inflation) remain pre-adjudication — not yet decided in court; Senate finding already priced; July 29 earnings call…

DOJ criminal and civil probes remain pre-adjudication; June 23 healthcare-fraud takedown is sector context; Senate finding already priced at 10.2; July 29 earn…

DOJ criminal and civil probes widened to Optum Rx physician reimbursement — all remain pre-adjudication; July 29 earnings call is the next information event.

DOJ criminal and antitrust probe into Medicare Advantage billing remains pre-adjudication; no new entity-named findings June 30; score holds.

DOJ criminal and antitrust probe into Medicare Advantage billing remains pre-adjudication; June 23 DOJ healthcare-fraud takedown is sector context, not entity-…

DOJ criminal and antitrust probe into Medicare Advantage billing remains pre-adjudication; June 23 DOJ healthcare-fraud takedown is sector context, not entity-…

DOJ criminal and antitrust probe into Medicare Advantage billing remains pre-adjudication; June 23 DOJ healthcare-fraud takedown is sector context, not entity-…

DOJ criminal and antitrust probe expanded to cover Medicare Advantage overbilling and Optum billing; score holds under the pre-adjudication rule.

DOJ criminal and antitrust probe expanded to cover Medicare Advantage overbilling, Optum Rx billing, and physician reimbursement; score holds under pre-adjudic…

DOJ criminal Medicare Advantage fraud probe now interviewing former employees; Optum Rx also under investigation; no new adjudicated evidence.

DOJ criminal probe expanded to Optum Rx and physician reimbursement; near-floor limitation active.

DOJ criminal probe now spans Medicare Advantage, Optum Rx, and physician reimbursement; Senate: 'aggressively' gaming risk scores.

DOJ MA risk-score probe and coordinated multi-AG investigations raise enforcement density; CEO churn; all pre-adjudication.

Coordinated state-AG investigations remain pre-adjudication; enforcement density rises without crossing to scored.

Coordinated multi-state AG investigation and CEO resignation resolved as pre-adjudication; enforcement density rises without crossing to scored.

DOJ grand-jury subpoena added to MA-fraud probe; AZ AG cartel suit; Lifepoint federal complaint.

DOJ grand-jury subpoena added to MA-fraud probe; AZ AG eight-insurer cartel suit; Lifepoint federal complaint.

DOJ criminal probe, AZ AG eight-insurer cartel suit, MultiPlan grand-jury subpoena, and Lifepoint federal complaint sustain near-floor enforcement density.

DOJ MA-fraud probe, AZ AG cartel suit, MA antitrust greenlight, and AI-denial class action sustain near-floor sovereign-enforcement density.

AZ AG June 1 eight-insurer algorithmic price-fixing cartel suit joins DOJ probe and MA AG $100M MassHealth fraud suit.

MA AG $100M MassHealth fraud suit and AZ AG eight-insurer price-fixing cartel suit filed in same window as DOJ MA-billing probe.

50-insurer prior-auth pledge announced but not verified for delivered effect; DOJ MA-billing probe and AI claim-denial class action remain priced negatives.

Prior-auth reductions announced but not verified for delivered effect; DOJ MA-billing probe and AI claim-denial class action remain priced negatives.

DOJ criminal probe expanded to Optum Rx and physician compensation; CEO departed; AI-claim-denial suit survived MTD.